RecruitingNCT07399730
Rare condition
Atypical hemolytic uremic syndrome
12
studies recruiting now
as of 7 Sept 2026
48
studies registered in total
as of 7 Sept 2026
15
countries with a recruiting site
as of 7 Sept 2026
10 Feb 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 3NCT05795140
Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS
RecruitingPhase 3NCT05935215
Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
RecruitingPhase 4NCT07308574
Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS
RecruitingNCT06312644
Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 12 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Atypical hemolytic uremic syndrome study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Atypical hemolytic uremic syndrome
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.
Treatments being studied
1 approved treatment and 6 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Eculizumab (Bekemv)
Phase 3Iptacopan
Phase 3Narsoplimab
Phase 3Crovalimab (Piasky)
Phase 3Ravulizumab (Ultomiris)
Phase 2Avacopan (Tavneos)
Phase 2Cemdisiran
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).